Recent developments highlight Actuate Therapeutics' clinical progress and pipeline expansion efforts, including positive Phase 2 trial data in metastatic pancreatic cancer and plans to advance the oral tablet formulation into Phase 1/2 trials in refractory cancers.

• Actuate Therapeutics announced plans to expand its clinical pipeline by advancing the Elraglusib oral tablet into a Phase 1/2 clinical program targeting refractory cancers [N2].
• The company reported positive follow-up data from its randomized controlled Phase 2 trial demonstrating extended long-term overall survival benefit with Elraglusib plus chemotherapy for metastatic pancreatic cancer, presented at ASCO GI 2026 [N3].
• Positive Phase II data were reported in salivary gland cancers, indicating potential broader applicability of Elraglusib [N4].
• Multiple news reports have highlighted encouraging clinical trial results and analyst interest in the company’s growth potential [N5][N6][N7].

The company has demonstrated statistically significant survival improvements in a difficult-to-treat cancer indication (mPDAC) with elraglusib plus chemotherapy, supported by positive Phase 2 data presented at a major oncology conference. The development of an oral tablet formulation expands potential indications and patient convenience. Encouraging early data in pediatric cancers and plans for multiple Phase 2 studies suggest a broad pipeline potential. Orphan drug and fast track designations may facilitate regulatory pathways. Strategic collaborations and AI-driven research partnerships may enhance development efficiency and patient targeting.

Actuate Therapeutics is a clinical-stage company with no approved products and a history of operating losses and negative cash flow. The company depends on raising additional capital to fund ongoing and planned clinical trials, with substantial doubt about its ability to continue as a going concern noted by auditors. Manufacturing relies on third parties without long-term supply agreements, posing supply chain risks. The oncology market is highly competitive with many established players. Clinical trial outcomes remain preliminary and subject to change. Failure to secure sufficient funding or regulatory approvals could materially impair operations and prospects.

Actuate Therapeutics’ moat is primarily based on its proprietary, patent-protected GSK-3β inhibitor elraglusib, which is one of the most advanced clinical-stage inhibitors targeting a novel mechanism in oncology. The company holds exclusive licenses from reputable academic institutions and benefits from orphan drug and fast track designations that may provide regulatory advantages. Its clinical data demonstrating survival benefits in metastatic pancreatic cancer and encouraging results in pediatric cancers support its scientific differentiation. However, the company faces significant competition from larger pharmaceutical and biotechnology firms with broader resources and multiple oncology programs. The lack of commercial products and reliance on third-party manufacturing and collaborations limit its current competitive positioning.

• Capital and Liquidity Risk: The company has incurred significant operating losses and has an accumulated deficit of approximately $154.6 million as of December 31, 2025. Cash and equivalents were $13.16 million at year-end, with liquidity sufficient only for near-term operations. The company requires substantial additional funding to continue clinical development and operations. Failure to raise capital on acceptable terms could force delays, reductions, or cessation of development programs or operations.
• Clinical Development Risk: Elraglusib is in clinical development with positive Phase 2 data but no approved products. Clinical trial results are preliminary and subject to change. Failure to demonstrate safety and efficacy in ongoing and future trials could prevent regulatory approval and commercialization.
• Supply Chain and Manufacturing Risk: The company relies on third-party manufacturers for clinical supply and has no long-term supply agreements. Disruptions, price changes, or inability to secure supply could delay clinical trials and commercialization.
• Competitive Risk: The oncology drug development field is highly competitive with many large pharmaceutical and biotechnology companies developing therapies targeting similar or alternative pathways. Competitors may have greater resources, broader pipelines, and more advanced products.
• Regulatory and Commercialization Risk: The company currently lacks sales, marketing, and commercial distribution capabilities. Building these capabilities or securing partnerships is necessary for commercialization. Regulatory approvals are required and subject to uncertainty.

• Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for difficult-to-treat cancers by inhibiting glycogen synthase kinase-3 beta (GSK-3β).
• The lead product candidate is elraglusib, an ATP-competitive small molecule GSK-3β inhibitor, developed under exclusive licenses from University of Illinois-Chicago and Northwestern University.
• Elraglusib is being developed in two dosage forms: an intravenous injection and an oral tablet, enabling targeting of multiple cancer types.
• The company has treated over 500 patients with elraglusib in Phase 1 and Phase 2 clinical trials.
• The most advanced clinical program is a randomized, controlled Phase 2 trial (Actuate-1801 Part 3B) for first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).
• Updated Phase 2 data presented at ASCO GI 2026 showed statistically significant improvement in median overall survival (mOS) for elraglusib plus gemcitabine/nab-paclitaxel (GnP) versus GnP alone (10.1 months vs. 7.2 months, p=0.02, HR=0.62).
• The 12-month survival rate nearly doubled (44.4% vs. 22.3%) and the 24-month survival rate increased almost fivefold (12.9% vs. 2.6%) in the elraglusib/GnP arm compared to control.
• Secondary endpoints such as overall response rate, median progression-free survival, and disease control rate showed numerical improvements with elraglusib combination.
• Elraglusib Injection is also being evaluated in pediatric cancers including Ewing sarcoma and neuroblastoma, with encouraging Phase 1 data and plans for Phase 2 trials.
• The oral tablet form is planned for Phase 1/2 clinical development in refractory cancers such as metastatic melanoma, colorectal cancer, and non-small cell lung cancer, subject to funding.
• The company holds Orphan Drug Designations and Fast Track Designation for pancreatic cancer and other cancer types.
• Actuate Therapeutics operates as a semi-virtual company with 12 full-time employees and relies on third-party manufacturers and contractors for clinical supply and development activities.
• The company does not currently have commercial sales, marketing, or distribution capabilities and plans to build these over time if product candidates advance.
• Financial snapshot as of December 31, 2025: cash and equivalents of $13.16 million, current assets of $13.64 million, current liabilities of $5.71 million, resulting in a current ratio of 2.39 and cash ratio of 2.31.
• The company reported a net loss of $22.23 million and basic and diluted EPS of -$1.06 for the fiscal year ended December 31, 2025.
• The company has incurred significant operating losses since inception with an accumulated deficit of approximately $154.6 million as of December 31, 2025.
• Liquidity and capital resources are a material risk; the company expects to require additional funding to continue operations and advance clinical programs.
• The company has no long-term supply agreements for elraglusib and relies on third-party suppliers, which could pose supply chain risks.
• The company faces competition from major pharmaceutical and biotechnology companies and academic institutions in oncology drug development.
• The company has strategic collaborations including a research partnership with Lantern Pharma to leverage AI for patient subtype identification.
• Recent news highlights include plans to expand the clinical pipeline with the oral tablet advancing into Phase 1/2 trials in refractory cancers [N2], positive follow-up Phase 2 data demonstrating extended overall survival benefit in metastatic pancreatic cancer [N3], and positive Phase II data in salivary gland cancers [N4].